CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

导出 OA

翻译打印收藏纠错

作者： Jatinder K,Lamba ^[1] ; Lata,Chauhan ^[1] ; Miyoung,Shin ^[1] ; Michael R,Loken ^[1] ; Jessica A,Pollard ^[1] ; Yi-Cheng,Wang ^[1] ; Rhonda E,Ries ^[1] ; Richard,Aplenc ^[1] ; Betsy A,Hirsch ^[1] ; Susana C,Raimondi ^[1] ; Roland B,Walter ^[1] ; Irwin D,Bernstein ^[1] ; Alan S,Gamis ^[1] ; Todd A,Alonzo ^[1] ; Soheil,Meshinchi ^[1]

作者单位： Jatinder K. Lamba, Lata Chauhan, and Miyoung Shin, University of Florida, Gainesville, FL; Michael R. Loken, Hematologics Inc; Rhonda E. Ries, Irwin D. Bernstein, and Soheil Meshinchi, Fred Hutchinson Cancer Research Center; Roland B. Walter and Soheil Meshinchi, University of Washington, Seattle, WA; Jessica A. Pollard, Maine Medical Center, Portland, ME; Jessica A. Pollard, Tufts University, Boston, MA; Yi-Cheng Wang, Children's Oncology Group, Monrovia; Todd A. Alonzo, University of Southern California, Los Angeles, CA; Richard Aplenc, Children's Hospital of Philadelphia, Philadelphia, PA; Betsy A. Hirsch, University of Minnesota, Minneapolis, MN; Susana C. Raimondi, St Jude Children's Research Hospital, Memphis, TN; and Alan S. Gamis, Children's Mercy Hospitals and Clinics, Kansas City, MO. ^[1]